Role of SGLT2 Inhibitors in the Nephrology Practice

The goal of this activity is to increase knowledge about the mechanism of action by which sodium–glucose cotransporter 2 (SGLT2) inhibitors can impact renal outcomes and to have greater competence in treating diabetic kidney disease in safe and effective ways.
 
Educational Partner: Medscape, LLC
 
Medium: Online Presentation
 
Commercial Support: Commercial Support: Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This activity is intended for nephrologists, primary care physicians, and diabetologists & endocrinologists.

Learning Objectives

Upon completion of this activity, participants will:
 
  • Have increased knowledge regarding the
    • Mechanism of action of SGLT2 inhibitors related to impact on renal outcomes
  • Have greater competence related to
    • Treating diabetic kidney disease in safe and effective ways
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
For more information, please contact:
CME Coordinator Contact Name: 
Medscape
CME Coordinator Contact Email: 
CME@medscape.net
Summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Activity opens: 
11/07/2019
Activity expires: 
11/07/2020
MODERATOR
  Ralph A. DeFronzo, MD
  Professor of Medicine
  University of Texas Health Science Center
  San Antonio, Texas
  United States
 
FACULTY
  Rajiv Agarwal, MD
  Professor of Medicine
  Indiana University School of Medicine
  Indianapolis, Indiana, United States
 
 
  Vlado Perkovic, MBBS, PhD
  Scientia Professor of Medicine
  George Institute
  UNSW Sydney
  Sydney, Australia

STEERING COMMITTEE MEMBER
  George L. Bakris, MD
  Professor of Medicine
  Director, AHA Comprehensive Hypertension Center
  University of Chicago Medicine
  Chicago, Illinois, United States

 

Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Other Healthcare Professions Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Registration: To view this activity, you will need to visit Medscape's website.
Click here to view the activity or if you are logged in click on the "Complete Activity" button!
 
Please login or create an account to proceed.